youtube_live
Penghasilan pada Q3 2026 • dirilis • EPS tidak tercapai -54,39% • Pendapatan tidak tercapai -5,83%
Lihat hasilchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
US$15,43
arrow_downward
-0,90%(-0,14) 1 HR
US$15,43
0,00% (0,00)
bedtimeSetelah jam perdagangan normal
Tutup: 6 Nov, 16.00.01 GMT-5 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk RARE...
Pembukaan
US$15,68
Tinggi
US$15,97
Rendah
US$15,12
Kapitalisasi pasar
1,52Â M
Volume rata-rata
3,88Â jt
Volume
4,05Â jt
Harga tinggi dalam 52 minggu terakhir
US$39,89
Harga rendah dalam 52 minggu terakhir
US$12,73
EPS
-US$5,19
Beta
0,37
Saham beredar
101,92Â jt
Jumlah karyawan
1Â rb
Pembukaan
US$15,68
Tinggi
US$15,97
Rendah
US$15,12
Kapitalisasi pasar
1,52Â M
Volume rata-rata
3,88Â jt
Volume
4,05Â jt
Harga tinggi dalam 52 minggu terakhir
US$39,89
Harga rendah dalam 52 minggu terakhir
US$12,73
EPS
-US$5,19
Beta
0,37
Saham beredar
101,92Â jt
Jumlah karyawan
1Â rb
Artikel berita
Dari sumber web dan partner berita
Yahoo Finance
·
3 hari yang lalu
Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Tentang Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Karyawan1,37Â rb
Didirikan2010
Kantor PusatNovato, California, Amerika Serikat
SektorHealth Care
Industri-
Situsultragenyx.com